Cargando…

Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains

Anticalin(®) proteins have been proven as versatile clinical stage biotherapeutics. Due to their small size (∼20 kDa), they harbor a short intrinsic plasma half-life which can be extended, e.g., by fusion with IgG or Fc. However, for antagonism of co-immunostimulatory Tumor Necrosis Factor Receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siegemund, Martin, Oak, Prajakta, Hansbauer, Eva-Maria, Allersdorfer, Andrea, Utschick, Karoline, Winter, Alexandra, Grasmüller, Christina, Galler, Gunther, Mayer, Jan-Peter, Weiche, Benjamin, Prassler, Josef, Kontermann, Roland E., Rothe, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573339/ https://www.ncbi.nlm.nih.gov/pubmed/34759826 http://dx.doi.org/10.3389/fphar.2021.759337

Ejemplares similares

Anticalin(®) Proteins as Therapeutic Agents in Human Diseases
por: Rothe, Christine, et al.
Publicado: (2018)

The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
por: Peper-Gabriel, Janet K., et al.
Publicado: (2022)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

Mapping Mechanostable Pulling Geometries of a Therapeutic Anticalin/CTLA-4 Protein Complex
por: Liu, Zhaowei, et al.
Publicado: (2021)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

Airway Wall Expression of OX40/OX40L and Interleukin-4 in Asthma
por: Siddiqui, Salman, et al.
Publicado: (2010)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Multimodality Multiparametric Imaging of Early Tumor Response to a Novel Antiangiogenic Therapy Based on Anticalins
por: Meier, Reinhard, et al.
Publicado: (2014)

High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide
por: Rauth, Sabine, et al.
Publicado: (2016)

Structural plasticity in the loop region of engineered lipocalins with novel ligand specificities, so-called Anticalins
por: Achatz, S., et al.
Publicado: (2021)

Anticalin N- or C-Terminal on a Monoclonal Antibody Affects Both Production and In Vitro Functionality
por: Aubrey, Nicolas, et al.
Publicado: (2022)

OX40L-OX40 Interactions: A Possible Target for Gastrointestinal Autoimmune Diseases
por: Mahmood, Tahrin, et al.
Publicado: (2012)

Crucial role of OX40/OX40L signaling in a murine model of asthma
por: Lei, Wei, et al.
Publicado: (2018)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
por: Zhou, Xiaoling, et al.
Publicado: (2022)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
por: Lé, Ana Maria, et al.
Publicado: (2022)

Design of a surrogate Anticalin protein directed against CD98hc for preclinical studies in mice
por: Deuschle, Friedrich‐Christian, et al.
Publicado: (2020)

Development of a high affinity Anticalin(®) directed against human CD98hc for theranostic applications
por: Deuschle, Friedrich-Christian, et al.
Publicado: (2020)

OX40/OX40L in systemic lupus erythematosus: Association with disease activity and lupus nephritis
por: Farres, Mohamed N., et al.
Publicado: (2011)

The OX40/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases
por: Fu, NanNan, et al.
Publicado: (2021)

Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
por: Fromm, George, et al.
Publicado: (2015)

The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response
Publicado: (1996)

Mast Cell-Derived Exosomes Promote Th2 Cell Differentiation via OX40L-OX40 Ligation
por: Li, Fei, et al.
Publicado: (2016)

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment
por: Chen, Peixin, et al.
Publicado: (2021)

Hsa_circ_0000652 Aggravates Inflammation by Activation of Macrophages and Enhancement of OX40/OX40L Interaction in Ankylosing Spondylitis
por: Song, Minkai, et al.
Publicado: (2021)

Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

GlycoTAIL and FlexiTAIL as Half-Life Extension Modules for Recombinant Antibody Fragments
por: Seifert, Oliver, et al.
Publicado: (2022)

OX40-OX40L Interaction Promotes Proliferation and Activation of Lymphocytes via NFATc1 in ApoE-Deficient Mice
por: Yan, Jinchuan, et al.
Publicado: (2013)

OX40L/OX40 Signal Promotes IL-9 Production by Mucosal MAIT Cells During Helicobacter pylori Infection
por: Ming, Siqi, et al.
Publicado: (2021)

New pathways in immune stimulation: targeting OX40
por: Alves Costa Silva, Carolina, et al.
Publicado: (2020)

Development of OX40 agonists for canine cancer immunotherapy
por: Ruiz, Damien, et al.
Publicado: (2022)

OX40:OX40L axis: emerging targets for improving poxvirus‐based CD8(+) T‐cell vaccines against respiratory viruses
por: Goulding, John, et al.
Publicado: (2011)

Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D)
por: An, Jingnan, et al.
Publicado: (2019)

First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors
por: Mross, Klaus, et al.
Publicado: (2013)

Communications in interference limited networks
por: Utschick, Wolfgang
Publicado: (2016)

Dual Anti-OX40/IL-2 Therapy Augments Tumor Immunotherapy via IL-2R-Mediated Regulation of OX40 Expression
por: Redmond, William L., et al.
Publicado: (2012)

OX40: a win–win path to tumor immunity
por: Sedwick, Caitlin
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_br46q1umoiqckveoth21h8u56b